Slide 1: Elevating the World’s Wellbeing
Elevating the World’s Wellbeing
Slide 2: Forward-looking statement
Q3 2025 f} Forward-looking statement This presentation contains certain forward-looking statements and opin- ions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording
Slide 3: Agenda
Q3 2025 Agenda Q3 in Short Business Updates Financial Results Strategy and Outlook Q&A Matthew Poulter Interim CFO
Slide 4: Q3 in Short
1.Q3 in Short
Slide 5: Proven profitability and cash discipline, now poised for renewed growth
Q3 2025 Proven profitability and cash discipline, now poised for renewed growth Q3 quarterly results 6% 200% 9% 297% 33% Pro forma revenue Year-on-Year quarterly Year-on-Year net cash- Adjusted EBITDA less Adjusted EBITDA margin growth recurring revenue flow growth to CAPEX growth to growth to €14.2
Slide 6: Quarterly Progress
Q3 2025 Quarterly Progress Stable revenue growth: Revenue €3.5m, up 6% YoY (+9% constant currency), reflecting continued SaaS momentum in Lifecare and disciplined execution across the Group. Sustained profitability and cash discipline: Pro forma Adjusted EBITDA €1.2m (33% margin) and Adjusted EBITDA
Slide 7: Our two business lines have us well-positioned to capitalise on increasing digital healthcare demand
Our two business lines have us well-positioned to capitalise on increasing digital healthcare demand and corporate wellbeing challenges. 20% Wellness One platform, all areas of employee wellbeing Technology for employers 80% Lifecare Seamless and efficient care solutions Technology for healthcare pr
Slide 8: Lifecare Quarterly update
Q3 2025 Stable Growth and Sustained Margin Strength Lifecare delivered 13% revenue growth year-on-year and maintained Lifecare Quarterly update its strong margin profile, with an Adjusted EBITDA margin of 48%. Growth was underpinned by pricing optimisation, resilient renewals, and continued strength
Slide 9: Wellness Quarterly update
Q3 2025 Wellness Quarterly update Strategic Transition Driving Sustainable Model Wellness revenue declined year-on-year, reflecting the planned expiry of legacy contracts and the continued pivot from one-off income streams toward a recurring SaaS-led model. ARR stood at €1.0m (+46% YoY, -20% QoQ), w
Slide 10: Strategic Restructuring: Building for the Future
Q3 2025 Strategic Restructuring: Building for the Future When we restructured in Q1 2025, we didn’t just cut costs. We took a comprehensive approach to building a more resiliant organisation: Minimum viable teams Core Innovation Capacity Modern Workflows Redefined team structures to maximize Protect
Slide 11: Financial Results
Q3 2025 Financial Results
Slide 12: Q3 Financial Highlights
Q3 2025 Q3 Financial Highlights Q325 Pro forma Anualised Q325 Adjusted Revenue revenue EBITDA €3.5m 6% €14.2m 5% €1.2m 25% (2024: €3.3m) (2024 (pro forma): €13.5m) (2024 (pro forma): €0.9m) Q325 annual recurring Q225 Adjusted Q225 Free- Subscription Revenue EBITDA less CAPEX Cashflow €12.7m 10% €0.4
Slide 13: Q3 Revenue Story
Q3 2025 Q3 Revenue Story Lifecare Wellness (pro forma) 3% q/q and 13% p/q Growth -18% q/q and -20% p/q (pro forma) Decline Churn remaining at 1% Decline across all Wellness entities as a result of seasonality within the Champion Health Nordic and Champion Health Plus business lines, alongside the pl
Slide 14: Profitability
Q3 2025 Profitability 01 2023 022023 03 2023 (pro-forma) adjusted EBITDA and margin (42073 i024 ©2204 a32021 ae 2024 SEEBEBITDA em €8ITDA Margin i 2025 a2 2025 03 2025 1a aa 10 os 04 02 00 una woH Adjusted EBITDA less CAPEX by quarter 13 €'million 2025 AD) EBITDA less CAPEX 2024 ADJ EBITDA less CAPE
Slide 15: Cash and Liquidity Position
Q3 2025 Cash and Liquidity Position Free cash flow €0.8m p/q cash generation growth Cash generation Available facility Four consecutive quarters of cash generation €0.2m repaid on the facility in current quarter €1.8m Q2 and Q3 cash generation compared to comparative period €1.4m available on facili
Slide 16: Balance Sheet
Q3 2025 Balance Sheet 30 31 September 2025 December 2024 Euros'000 Goodwill, intangibles and PPE 24,050 26,413 Cash and cash equivalents 603 723 Borrowings (4,038) (4,808) Trade and other receivables 1,865 2,992 Trade and other payables (2,365) (3,123) Deferred revenue (1,920) (2,011) Deferred tax (
Slide 17: Strategy and Outlook
Strategy and Outlook
Slide 18: Our Unique Value Proposition
Our Unique Value Proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes through more personalized, data-driven care Positioned to capitalize on growt
Slide 19: How it all comes together - Investing in Physitrack
How it all comes together - Investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Physitrack aims to achieve a doubling of revenue within the medium term, replacing Growing market supported by 1. Market growth dynamics the previous target set i
Slide 20: Q&A
Q&A